





**Emerging
immunotherapies
in cancer**

**Breaking through emergent immunotherapy
and immune targets in cancer**

Thursday 26th September, 2019

Casa de Convalescència, Barcelona



**FIGHT AIDS
FOUNDATION**

08.30	Registration	
09.00	Welcome	Leticia De Mattos , IrsiCaixa Institute of Research, Barcelona.


MORNING SESSION

TABLE I: CANCER AND THE IMMUNE SYSTEM: WHERE ARE WE HEADING TO		CHAIR: Leticia De Mattos , IrsiCaixa Institute of Research, Barcelona.
09.15	Cancer and the immune system: basic concepts and targets for therapy intervention	Jorge Carrillo , IrsiCaixa Institute of Research, Barcelona.
09.35	Predictive molecular factors of response beyond PD-L1 expression	Rafael Rosell , Hospital Universitari Dexeus, Barcelona.
09.55	Overall discussion	
TABLE II: ACTIVATING VIRAL DEFENSE SIGNALING IN CANCER		CHAIR: Antoni Ribas , University of California Los Angeles, USA.
10.10	Innate immune agonists to improve the immunobiology of the tumor microenvironment	Thomas Gajewski , Chicago University, USA.
10.30	Taking a “toll” on cancer: combination strategies to overcome immune resistance	Ted Everson , Idera Pharmaceuticals Inc., USA.
10.50	Intratumoral BO 112: viral mimicry in cancer therapy	Iván Márquez , Hospital Gregorio Marañón, Madrid.
11.10	Overall discussion	
11.25	Coffee break	
TABLE III: IMMUNO ONCOLOGY THERAPEUTIC STRATEGY		CHAIR: Maria González-Cao , Hospital Universitari Dexeus, Barcelona.
11.55	Neoadjuvant immunotherapy in lung cancer	Mariano Provencio , Grupo Español de Cáncer de Pulmón, Madrid.
12.15	Novel approaches beyond PD-1 inhibitors	Luis Paz-Ares , Hospital Universitario 12 de Octubre, Madrid.
12.35	Future Directions for CAR-T Therapy	Manel Juan Otero , Hospital Clínic de Barcelona.
12.55	The role of CD40 in cancer immunotherapy	Ovid C. Trifan , Apexigen Inc., USA
13.15	Overall discussion	

TABLE IV: PERSONALIZED NEOANTIGEN VACCINE		CHAIR: Manel Juan Otero, Hospital Clínic de Barcelona.
13.30	Neoantigen identification as targets for cancer vaccines	Leticia De Mattos , IrsiCaixa Institute of Research, Barcelona.
13.50	eVLPs in cancer: from HIV vaccine to cancer therapy	Julià Blanco , IrsiCaixa Institute of Research, Barcelona.
14.10	Overall discussion	
14.25	Lunch break	

AFTERNOON SESSION

TABLE V: NEW INSIGHTS: VIRUS, BACTERIA AND CANCER		CHAIR: Bonaventura Clotet, IrsiCaixa Institute of Research, Barcelona.
15.25	Cancer virotherapy	Ramon Alemany , IDIBell, Barcelona.
15.45	Results of phase II study of durvalumab in cancerpatients with HIV-1 infection (DURVAST trial)	Maria González-Cao , Hospital Universitari Dexeus, Barcelona.
16.05	Reinvigorating exhausted T cell responses in chronic virus infections	Andreas Meyerhans , Pompeu Fabra University, Barcelona.
16.25	Microbiome in cancer	Thomas Gajewski , Chicago University, USA.
16.45	Overall discussion	
17.00	Closing lecture: Overcoming resistance to PD-1 blockade therapy	Antoni Ribas , University of California Los Angeles, USA.
17.30	Closure of the event	



This activity has been accredited by the Comisión de Formación Continuada del Sistema Nacional de Salud and by the Consell Català de la Formació Continuada de les Professions Sanitàries with **0,8 credits** and registered with the **num. 09/025744-MD**.

With the scientific endorsement of



Sponsored by



Bristol-Myers Squibb



NOVARTIS



AstraZeneca



Lilly



idera